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Abstract
Compelling evidence indicates that the endothelium-derived
potent vasoconstrictor endothelin-1 (ET-1) stimulates aldo-
sterone secretion by interacting with specific receptors. Al-
though two different ET-1 receptors have been identified
and cloned, the receptor subtype involved in mediating aldo-
sterone secretion is still unknown. Accordingly, we wished
to investigate whether the genes of ET-1 and of its receptors
A and B are expressed in the normal human adrenal cortex.
We designed specific primers for ET-1 and the ETA and
ETB receptors genes and developed a reverse transcription
polymerase chain reaction (RT-PCR) with chemilumines-
cent quantitation of the cDNA. In addition, we carried out
'I ET-1 displacement studies with cold ET-1, ET-3 and the
specific ETA and ETB ligands BQ123 and sarafotoxin 6C.
Localization of each receptor subtype was also investigated
by autoradiography. Binding experiments were first individ-
ually analyzed by Scatchard and Hofstee plot and then co-
analyzed by the nonlinear iterative curve fitting program
Ligand. Histologically normal adrenal cortex tissue, ob-
tained from kidney cancer patients (n = 7), and an aldoste-
rone-producing adenoma (APA), which is histogenetically
derived from the zona glomerulosa (ZG) cells, were studied.
Results showed that the ET-1, ETA and ETB mRNA can be
detected by RT-PCR in all adrenal cortices as well as in the
APA. The best fitting of the 125I ET-1 displacement binding
data was consistently provided by a two-site model both in
the normal adrenal cortex (F = 22.1, P < 0.0001) and in
the APA (F = 18.4, P < 0.0001). In the former the density
(B..n) of the ETA and ETB subtype was 2.6±0.5 pmol/mg
protein (m±SEM) and 1.19±0.6, respectively. The dissocia-
tion constant (Kd) of ET-1, ET-3, S6C, and BQ-123 for each
receptor subtype resulted to be within the range reported
for human tissue for the ETA and ETB receptors. In the
APA tissue the B.,. tended to be lower (1.33 and 0.8 pmol/
mg protein, for the ETA and ETB, respectively) but the
Kd were similar. Autoradiographic studies confirmed the
presence of both receptor subtypes on the ZG as well as on
APA cells. Thus, the genes of ET-1 and both its receptor
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subtypes ETA and ETB are actively transcribed in the human
adrenal cortex. Furthermore, both receptor subtypes are
translated into proteins in ZG and APA cells. (J. Clin. Invest.
1994.94:1226-1234.) Key words: aldosterone * adrenal cor-
tex * endothelin * receptors subtypes * sarafotoxin * antago-
nists
Introduction
The secretion of aldosterone is regulated by several factors.
The three major secretagogues are angiotensin H, ACTH, and
potassium, whereas dopamine, sodium, and the atriopeptins ex-
ert an inhibitory effect ( 1). Recently, the very potent 21 -amino
acid vasoconstrictor peptide endothelin-1 (ET-1),' has also
been shown to stimulate aldosterone secretion both in vitro and
in vivo (2-7), and to enhance ACTH- and. angiotensin H-
stimulated aldosterone secretion from cultured bovine adrenal
cells (8, 9). Furthermore, it has been reported that the chronic
infusion of ET-1 raises plasma aldosterone concentration in rats
and that isolated zona glomerulosa (ZG) cells from the infused
animals showed an enhancement of their basal production of
aldosterone, which was consistent with de novo synthesis of
the aldosterone-synthesizing enzymes (10, 11). Accordingly, it
has been hypothesized that ET-1 plays a role in the regulation
of aldosterone in several conditions, including liver cirrhosis
( 12), congestive heart failure ( 13, 14), preeclampsia ( 15 ), liver
transplantation ( 16, 17), endotoxiemic shock ( 18), primary and
malignant hypertension (19, 20), which are characterized by
enhanced aldosterone secretion and endothelial damage. Indeed,
the latter can turn-on synthesis and secretion of ET-1, and
thereby enhance aldosterone secretion through endocrine-para-
crine mechanisms. Since the chronic infusion of ET-1, a well
known mitogen (10), was found to cause a notable hypertrophy
of ZG cells it is also conceivable that ET-1 may be involved
in enhancing aldosterone secretion in primary aldosteronism, a
rare cause of secondary hypertension where no known stimulus
of aldosterone secretion has been identified so far (1).
Two different ET-1 specific receptors, the ETA and ETB,
which have been identified, pharmacologically characterized,
and cloned (21), appear to mediate the physiological effects of
ET-1. Autoradiographic evidence of ET-1 specific binding to
the adrenal cortex and medulla has been reported in several
species (22-26). ET-1 specific binding to the ZG has been
consistently identified in rat, porcine and human adrenals (23,
26, 27), as well as to cultured calf adrenal ZG cells (2). Al-
though the data suggested the presence of two ET-1 receptors
1. Abbreviations used in this paper: APA, aldosterone-producing ade-
noma; EDRF, endothelium-derived relaxing factor; ET-1, endothelin-1;
RT, reverse transcription; S6C, sarafotoxin 6C; ZG, zona glomerulosa;
ZF, zona fasciculata.
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(26), no selective endothelin antagonist was available at that
time and therefore no conclusive information on whether ET-1
receptor subtypes exist in the adrenal cortex could be gained.
In vitro experiments with ET-1, ET-2, ET-3, and the weak ETB
agonist sarafotoxin B have thereafter suggested, although not
conclusively proven, the presence of a high and a low affinity
binding site in cultured calf glomerulosa cells (26). Further-
more, mRNA for both the ETA and the ETB receptor has been
detected by Northern blot analysis by Imai et al. (27) in three
human adrenal glands obtained from patients with an aldoste-
rone producing adenoma. However, ET-1 saturation isotherms
were consistent with the existence of only one population of
ET-1 receptors, suggesting that only one receptor subtype
mRNA was effectively translated into protein. Thus, the ques-
tion on whether endothelin receptor subtypes with possible dif-
ferent functional role exist in the normal human adrenal cortex
is still unanswered.
The recent development of the selective antagonist for the
ETA receptor BQ123 and of the weak ETB receptor agonist
sarafotoxin 6C (S6C) has provided new tools for investigating
the distribution and pharmacological properties of endothelin
receptors. Furthermore, molecular medicine techniques such as
the reverse transcription polymerase chain reaction (RT-PCR)
allowed investigating genes expression in different organs start-
ing from very limited amount of tissue, such as that available
in the clinical setting.
Thus, the purpose of this study was to investigate whether
ETA and ETB receptors are expressed in the normal human
adrenal cortex and to assess their anatomical distribution as well
as their binding properties. To further establish whether the ETA
and ETB receptors are present in the ZG, an adrenal tumor, the
aldosterone-producing adenoma (APA), which is histogeneti-
cally derived from ZG cells, was also studied.
Methods
Preparation of adrenal tissues. Adrenal cortices were obtained from
consenting patients undergoing unilateral nephrectomy for kidney can-
cer (n = 7). All adrenals were histologically normal. To rule out the
possibility of contamination from the medulla, that is rich in ET-1
binding sites, the utmost care was taken to dissect out only the outer
portion of the adrenal cortex. In addition, we studied an APA obtained
at surgery from a patient with primary aldosteronism. In this case the
surrounding histologically normal cortex and renal cortex biopsy tissue
served as controls for the gene expression studies. After excision, tissues
were immediately frozen in liquid nitrogen and stored at -1950C until
they were used for ET-1 binding studies, nucleic acid extraction, and
autoradiography.
Binding study. Samples were homogenized with a Polytron homoge-
nizer in 0.25 M sucrose at 40C and then centrifuged at 11,000 g for 60
min at room temperature. The pellets were resuspended in 0.05 M Tris-
HCl buffer, pH 7.4, with 5 mM MgCl2, 1 ILM aprotinin, 0.1% bacitracin,
0.5 mM phenylmethylsulphonylfluoride according to the method of
Nguyen et al. (28) with minor modifications. Protein concentration was
measured with a Lowry modified method (DC Protein Assay; Bio Rad
Laboratories, Milano, Italy). For binding studies, membrane suspen-
sions ( 15-25 gg protein) were incubated with 25 pM "2I ET-1 (Amer-
sham Laboratories, Amersham, Buckinghamshire, U.K.; specific activity
2,000 Ci/mmol) in the absence and presence of increasing concentra-
tions of unlabelled ET-1, ET-3, the specific ETB agonist S6C (29)
(Sigma Aldrich, Milano, Italy) and the specific ETA antagonist BQ123
(Peninsula Laboratories Inc., Merseyside, U.K.). Nonspecific binding
was determined in presence of a large amount of unlabeled ET-1 (100
nM). Based on previous studies, which have established the time re-
quired to attain equilibrium conditions, incubation was carried out for
2 h at room temperature (30, 31). Total radioactivity was counted in a
y counter and the free radioactive ET-1 was removed by centrifugation.
The pellets were washed for three times with the same buffer and then
counted. All experiments were carried out in duplicate.
Analysis. The binding experiments were analyzed by the nonlinear
iterative curve fitting program LIGAND developed by Munson and co-
workers (32, 33) (Ligand, Biosoft, Cambridge, U.K.). No correction
for the decay of "2I was applied since this has been shown to. cause
inappropriately high estimates of Bma. and Kd over time (34). Saturation
and competition binding data were analysed using EBDA to obtain
Hill coefficients (saturation experiments) and pseudo-Hill coefficients
(competition experiments) and LIGAND to obtain preliminary estimates
of the dissociation constant (Kd) and receptor density (B,,,) values.
Data files were run simultaneously with LIGAND to obtain final parame-
ter estimates. The presence of one, two, or three sites was tested using
the F-ratio test in LIGAND. The model adopted was that which provided
the significantly best fit (P < 0.05).
RNA preparation. Total RNA was isolated either by a modification
of the LiCl (35) or by the guanidium isothiocyanate methods. After
isolation, total RNA samples were checked by gel electrophoresis in an
1% agarose gel stained with EtBr after denaturation with 6 M glyoxal,
0.25 M DMSO, and 0.1 M NaH2PO4, pH 7.0. The purity of the extracted
RNA was also controlled by recording the UV absorbance of each
sample between 200 and 300 nm wavelength; concentrations of total
RNA were then calculated by spectrophotometric measurements at 260
nm wavelength.
Amplification method. For use in the polymerase chain reaction,
total RNA was reversely transcribed to cDNA according to Wang et al.
(36, 37). 5 jig of total RNA was dissolved in 100 ,.d of a mixture
containing (final concentration) 1 mM of dATP, dGTP, and dTTP,
dCTP, 1 U/I1 of RNAsin, 2.5 jLM Random Hexamers, 50 mM KCl,
10 mM Tris-HCl, pH 8.3, 5 mM MgCl2, and 2.5 U of cloned Moloney
Murine Leukemia Virus reverse transcriptase (M-MLV-RT; GeneAmp
RNA PCR Kit; Perkin Elmer, Norwalk, CT). After incubation at 42°C
for 15 min, temperature was raised to 99°C for 5 min and then reaction
mixture tubes were quickly chilled on ice. For amplification of the
resulting cDNA, 20 ILI of the reverse transcription mixture were used.
The sample volume was increased to 100 ILI with a solution containing
50 mM KC1, 10 mM Tris, pH 8.3, 2 mM MgCl2, 0.02 mM digoxigenin-
dUTP (Boheringer Mannheim, Milano, Italy) and 0.1 1uM of up- and
downstream primers as well as 2.5 U of Taq polymerase (AmpliTaq
DNA Polymerase; Perkin Elmer/Cetus). The thermal profile used in a
5600 Perkin Elmer Cetus thermal cycler included a denaturation step
at 95°C for 1 min, annealing at 54°C for 1 min and extension step at
72°C for 1 min for a total of 36 cycles. An additional extension step at
the temperature of 72°C for 7 min was then carried out. The 5' (up-
stream) primer for ET-1 consisted of 20 bp(183-203): AGA GTG
TGT CTA CTT CTG CC and the 3' primer of 19 bp (606-625: GCG
TTA TGT GAC CCA CAA C) (37). Both the 5' and 3' primers used
for the human ETA gene receptor consisted of 18 bases corresponding
to sequences 830-847 (CGC TGA TAG CCA GTC TTG) and 1482-
1499 (CGG TTC TTG TCC ATT TCG), respectively (38). For the
ETB gene receptor the 5' primer consisted of 19 bases (511-529: GGA
CCC ATC GAG ATC AAG G) and the 3' primer of 21 bases ( 1251-
1271: AGA ATC CTG CTG AGG TGA AGG) (39).
To assess the kinetics of the PCR amplification reaction 5-,41 aliquots
of the PCR products of each gene were collected at each cycle starting
from the 19th. As a positive control, amplification of a 838-bp fragment
of the human ,6-actin gene was carried out in parallel using the following
primers: 5' (upstream) 5' ATC TGG CAC CAC ACC TTC TAC AAT
GAG CTG CG 3' and 3' (downstream) 5' CGT CAT ACT CCT GCT
TGC TGA TCC ACA TCT GC 3' (Clontech Laboratories, Palo Alto,
CA). As a further control, RNA from the plasmid pAW1O9 was re-
versed-transcribed and amplification of a 308 bp fragment of an IL-la
site was carried out (GeneAmp RNA PCR Kit, Perkin Elmer). To rule
out the possibility of amplifying genomic DNA, in some experiments
the PCR was carried out with no prior reverse transcritpion of the RNA.
Detection of mRNA. Detection of the PCR amplification products
was first carried out by size-fractionation on 1.5% agarose gel electro-
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Figure 1. '25I ET-l displacement experiments by unlabeled ET-1
(o), ET-3 (<o), BQ123 (-), and safarotoxin S6C (*) in five
normal human adrenal cortices. It is evident that ET-1 was the most
potent in displacing '"I ET-1, followed by Sarafotoxin 6 C (S 6 C),
ET-3 and BQ123. Note that curves for (S 6 C) and BQ123 are
biphasic, suggesting two binding sites.
phoresis followed by Southern vacuum blotting (LKB, Pharmacia) onto
a nylon membrane. To further evaluate the kinetic of the amplification
reaction slot blot analysis was carried out with a commercially available
apparatus (Milliblot, Millipore, Milano, Italy). The PCR products trans-
ferred on a nylon membrane (Zeta-Probe GT; Biorad Laboratories, Mi-
lano, Italy) were UV cross-linked (Stratagene UV-Crosslinker 1800;
Stratagene-Duotech Milano, Italy). Detection of the digoxigenin-labeled
amplification products on the nylon membrane was carried out by a high
affinity antidigoxigenin-antibody Fab-fragments conjugated to alkaline
phosphatase using a chemiluminescent detection kit (DIG; Boehringer
Mannheim, Germany). Light generated via dephosphorilation of the
chemiluniscent substrate was used to impress XAR x-ray (Eastman
Kodak Co., Rochester, NY) films with a 20-min exposure, as in an
autoradiographic procedure. Quantification of the PCR products was
carried out by measuring the integrated optical density of the autoradio-
graphies with an image analyzer IBAS 2000 (Zeiss, Unterkochen, Ger-
many). Plots of the log integrated optycal density vs number of cycles
were then elaborated; the cycle number (N50) that corresponded to the
half-maximal PCR products was also calculated, as an estimate of the
relative amounts of initial amplifiable template of the f3-actin, ETA, and
ETB genes (40).
Autoradiography. Two normal adrenal cortices (including the cap-
sule) and one APA immediately frozen in isopentane cooled in liquid
nitrogen in the operating room were studied. Frozen 10- 15-'sm sections
were cut in a cryostat (Leitz 1720 Digital; Leitz, Wetzlar, Germany) at
-20°C, and processed according to Kuhar (41) and Palacios et al. (42).
Sections were preincubated in Tris-HCl 50 mM, pH 7.4, containing
0.01% bacitracine, 135 mM NaCl, 10 mM MgCl2, 1 mM tetrasodic
EDTA, 0.2% BSA, for 15 min at 20°C. ET-l binding sites were labeled
in vitro by incubation for 120 min with 100 pM "2I ET-1 (Amersham
Laboratories, Amersham, Buckinghamshire, U.K.; specific activity
2,000 Ci/mmol) at room temperature; nonspecific binding was deter-
mined by adding 1 liM cold ET-1. Selective displacement of '25I ET-1
was studied by adding 500 nM BQ-123 or 100 nM sarafotoxin 6C.
Reaction was terminated by washing three times the samples in 50 nM
Tris-HCl buffer. After rinsing in distilled water, the sections were rap-
idly dried, fixed in paraformaldehyde vapors at 80°C for 120 minm and
then coated with NTB2 Kodak Nuclear emulsion (Eastman Kodak Co.).
Table l. Hill (for ET-J) or Pseudo-Hill Coefficients (nH) (for ET-
3, Sarafotoxin 6 C [S 6 C] and BQ123), F-Ratio and Significance
of the Two- vs One-Site Model Fitting in the Normnal Human
Adrenal Cortex
Kd
n nH F-ratio Significance ETA ETB
nM nM
ET-1 6 0.74±0.06 4.75 P = 0.033 0.047±0.006 400±50
ET-3 5 0.56±0.16 2.84 P = 0.022 47±52.6 0.46±0.005
S 6 C 3 0.47±0.19 5.7 P = 0.009 33.0±41 0.88±0.42
BQ123 4 0.37±0.05 5.36 P = 0.027 5.5±0.45 426±383
Kd = Dissociation Constant values for ET-1, ET-3, S 6 C, and BQ123.
The autoradiograms were exposed for 2 wk at 40C, and then developed
with undiluted DI9 Kodak developer. They were stained with hematoxy-
lin-eosin, and observed and photographed with a Leitz Laborlux micro-
scope.
Statistical analysis. Mean±SEM are used to report the results. Com-
parison between groups was performed by Student's t test for unpaired
data and Mann-Whitney non-parametric test (43). Statistical analysis
was performed with SPSS/PC+ statistical package (SPSS Inc, Chi-
cago, IL).
Results
12" ET-J displacement binding. The results of the 1"I ET-l
displacement studies from the five normal human adrenal corti-
ces are shown in Fig. 1. Cold ET-1 was the most potent in
displacing 125I ET-l followed by S6C, ET-3, and BQ123. As it
can be seen, both S6C and BQ123 produced biphasic competi-
tion binding curves, suggesting the presence of two binding
sites. Analysis of the saturation and displacement experiments
showed Hill and pseudo-Hill coefficient values less than unity
for all ligands, suggesting the presence of multiple binding sites
(Table I). Further analysis with the nonlinear curve-fitting pro-
gram LIGAND revealed that the best fitting was provided by a
two-site model, as shown by the significant values of the F-
ratio (Table I) (32). Simultaneous analysis of the results of the
125I ET-1 binding displacement with ET-1, S6C and BQ123
using the LIGAND subroutine again showed that a two-site
model provided the best fitting of the experimental data (F-
ratio 22.07, P < 0.0001). The estimated Kd and B,,,,, values
are shown in Table I; they resulted to be within the ranges that
have been reported for the human myocardium by Molenaar et
al. (44) with a sophisticate quantitative autoradiographic tech-
nique. The specific ETA antagonist BQ123 did not allow to
displace '"I ET-1 completely, even at the highest concentration
of 100 ,tM that was used. Similar biphasic displacement curves
and curvilinear Hofstee plots were obtained in the Pt with APA,
thereby suggesting the presence of two classes of ET- 1 receptors
also in this tissue. This was further confirmed by the significant
value of the F-ratio (F = 18.42, P < 0.0001), by the results
of RT-PCR (Fig. 2 B, see below) and the autoradiographic
findings (see Fig. 6, and below). Estimated B.,X were lower
(1.33 and 0.8 pmol/mg protein), whereas the Kd were identical
to those of Table I.
PCR results. The RT-PCR consistently allowed detection
of the ET-1, ETA, and ETB mRNA in all adrenal specimen
examined. An example of an EtBr stained 1.5% agarose gel is
shown in Fig. 2. As it can be seen, amplified cDNA fragments
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Figure 2. (A) 1.5% agarose gel showing cDNA amplified with ET-1,
and with ETA and ETB receptor specific primers from a normal human
adrenal cortex. Lane 1 was loaded with 200 ng of a size marker
(PhiXl74 Hae III). The amplified fragments resulted to be of the ex-
pected size, which was 442, 669, and 760 bp for the ET-1, ETA, and
ETB, respectively. Amplification of a 838-bp fragment of the /3-actin
cDNA, as a positive control, is also shown. (B) Southern blot of the
same agarose gel after chemiluminescent detection demonstrates the
absence of nonspecific products, which could have been anticipated
given the 70% homology between the ETA and ETB receptor subtypes
cDNAs.
of the expected size for both the ETA and ETB receptors and
for the control f3-actin gene were easily detected, both in the
normal adrenals (Fig. 3 A) and in the APA tissue (Fig. 3 B).
In the latter, a notable difference is evident in the expression
of the ETA and ETB receptor between both normal and adenoma-
tous adrenal cortex tissue and the renal cortex, despite no evi-
dent difference in the expression of the /3-actin gene. No ampli-
fication was seen in the control PCR containing either no cDNA
(water) or total RNA with no prior reverse transcription, thereby
ruling out the possibility of false positive results and of amplifi-
cation of genomic DNA, respectively (Fig. 3).
An x-ray film of a slot-blot containing the amplification
products of different PCR cycles from two of the five normal
adrenal cortices is shown in Fig. 4. The kinetics of amplification
of the ETA, the ETB and the f3-actin cDNA is reported in Fig.
5, where the log of integrated OD of amplified DNA is plotted
vs number of PCR cycles. The ETA curve is shifted to the right
as compared with the others; the slopes of the ETA and ETB
amplification are similar, thereby suggesting a similar efficiency
of amplification (40). The N50, i.e., the number of cycles at
which half-maximal amplification was attained, resulted to be
significantly lower (P < 0.05) for ETB (22.56±1.53) than for
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Figure 3. (A) Agarose gel showing cDNA amplified with ETA and ETB
receptor-specific primers from five different normal human adrenal corti-
ces. The amplified fragments resulted to be of the expected size, which
was 669 and 760 bp for the ETA and ETB, respectively. Amplification
of a 838-bp fragment of the ,B actin cDNA, as a positive control, and
lack of amplification with no DNA template, as a negative control, are
also shown. Amplification of RNA with no prior reverse transcription
(RNA no RT) is also shown in lane 2. (B) Agarose gel showing cDNA
amplified with ETA and ETB receptor-specific primers from an aldoste-
rone-producing adenoma, the surrounding histologically normal adrenal
cortex and a kidney biopsy. Amplification of the /3-actin cDNA, as a
positive control, and lack of amplification with no DNA template, as a
negative control, are also shown.
ETA (26.66±0.74), and might suggest a lower initial abundance
of ETA mRNA (40).
Autoradiographyfindings. 1"I ET-1 binding was intense in
the subcapsular ZG, while in the zona fasciculata it was very
weak and clearly confined to the capillaries running between
adjacent parenchymal cords. Adrenal capsule was not labeled,
whereas extracapsular vessels displayed evident '"I ET-1 bind-
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Figure 4. Luminescence-exposed x-ray film of a slot-blot containing
the RT-PCR products (after 36 cycles) of the ETA and ETB, and the
,/-actin genes in two of the seven normal adrenal cortices studied. Detec-
tion was carried out as described in the text. Please note the presence
of both ETA and ETB expression as well as that of the positive control
,3 actin in the samples.
ing on both their muscular and endothelial components (Fig. 6
A). The addition of an excess of cold ET-1 virtually displaced
all 125I ET-1 binding (Fig. 6 B). BQ-123 markedly attenuated
labeling in ZG and completely eliminated it in the vascular
tunica muscularis, without apparently affecting 125I ET-1 of the
capillary endothelium in ZF (Fig. 6 C). Sarafotoxin 6C deter-
mined a moderate attenuation of ZG and completely eliminated
it in ZF; however, vascular smooth muscle cells were still la-
beled (Fig. 6 D). Similar results, but a less intense binding to
parenchymal cells, were obtained on the APA tissue (Fig. 7).
Discussion
Endothelins are a family of recently discovered peptides with
multiple biological actions, including very potent and long-last-
ing vasoconstriction, mitogenesis, and stimulation of endothe-
lium-derived relaxing factors (EDRFs), ANP, renin, arginin-
vasopressin, and aldosterone release (45, 46). In anesthetized
dogs the infusion of endothelin, aside from widespread hemody-
namic effects, consistently induced a two-four-fold long-last-
ing increase of aldosterone secretion, as well as an increase of
plasma renin activity (4). However, the stimulation of aldoste-
rone secretion appeared to be independent of the renin-angio-
tensin system, since it was observed also in vitro in dispersed
ZG cells (2, 3, 1 1 ), and even after pretreatment with the angio-
tensin converting enzyme inhibitor captopril (46). Further stud-
ies have indeed shown that ET-1 directly stimulates aldosterone
secretion, although less potently than angiotensin II, via a Ca2+-
dependent mechanism (7, 47). This stimulation is deemed to
involve enhancement of the synthesis of prostaglandins, since
in perfused slices of frog adrenal gland it was associated with
a release of prostaglandins and was abolished by indomethacin
(7). In addition, ET-1 potentiates the aldosterone response to
angiotensin II and ACTH (8, 9), possibly via an interaction
with different receptor subtypes (26). Of interest, ACTH has
been found to increase the release of endothelin-1 from the
adrenals thereby suggesting that ET-1 is a mediator of ACTH-
stimulated aldosterone secretion (48). In vitro binding experi-
ments on calf adrenal cultured glomerulosa cells have shown
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Figure 5. Kinetics of amplification of the ETA (n), ETB. (o) and fi-
actin (A) cDNA in the normal adrenal cortices studied. Plot of Log(inte-
grated optical density of amplified DNA) on the ordinate scale vs num-
ber of PCR cycles. Note the different slope of the linear portion of the
/l-actin curve, which suggests a higher efficiency of amplification, as
compared to both the ETA and the ETB curve, which appear to have a
similar slope.
the presence of specific, saturable endothelin binding sites with
an average Kd of 0.086 nM (2). However, this was not a proof
of the existence of only a single class of ET-1 receptors, given
the selectivity ratio of ET-1 for the two identified receptors
ETA and ETB and their similar relative densities. Therefore, no
conclusion could be made based on ET-1 saturation binding
isotherms alone (32, 33). Further studies on the same experi-
mental model with the endothelin analogue sarafotoxin 6 B,
which was equipotent to ET-1 in stimulating aldosterone secre-
tion, and with ET-3, a very poor stimulator of aldosterone secre-
tion, have thereafter suggested the presence of two different
endothelin receptors; a high-affinity (Kd of 0.05 nM) and a
low-affinity (Kd of 0.17 nM) receptor (26). Our study takes
advantage of two facts: the recent identification and cloning of
two human endothelin receptors (38, 39, 49) and the develop-
ment of specific antagonists for each one of them (29, 50).
The isopeptide-selective ETA receptor, identified from a human
cDNA library (21, 38) preferentially binds ET-1 and is specifi-
cally antagonised by BQ123. Its mRNA has been detected in
the central nervous system as well as in the aorta, heart and
lung (21). At variance, the nonisopeptide-selective ETB was
found to bind ET-1, ET-2, and ET-3 with the same affinity and
to be antagonised by S6C (29, 51). It is considered to be present
on endothelial cells where it can mediate the release of EDRFs
(50), but also on vascular and nonvascular smooth muscle
cells (52).
The results of this study show that these two endothelin
receptors are expressed in the human adrenal cortex as transcrip-
tion and translation products. 1251 ET-1 displacement binding
curves carried out in these extracts with ET-1, ET-3, and with
BQ123 and S6C, two selective antagonists for the ETA and ETB
receptor, revealed Hill and pseudo-Hill coefficients less than
unity (Table I), indicating multiple binding sites. Furthermore,
coanalysis of the binding curves obtained with the different
agonists and antagonists showed that the best fitting of the
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Figure 6. Autoradiographs of frozen sections of human adrenal glands incubated with '25I-ET-1 (100 pM). (A) Binding is well distributed and more intense
to the zona glomerulosa (ZG) than to the zona fasciculata (ZF), where it is mainly located on the capillaries running among the parenchymal cords. (B)
1251 ET-l is completely displaced by the addition of a 1-pM cold ET-1. (C) BQ-123 slightly attenuates binding to the ZG cells, while it does not affect
labelling to endothelium of the capillaries of ZF; in addition, it completely displaces "I ET-1 binding to the tunica media of the arterioles (asterisks) in the
capsule (C). (D) Sarafotoxin 6C attenuates "2I ET-l binding to ZG cells while it eliminates that to the endothelium (arrows) of capillaries in ZF; the
binding to the muscular wall of capsular arterioles is not affected. C gland capsule, *lumen of extracapsular vessels. Magnification x 140 for all sections.
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Figure 7. Autoradiographs of fro-
zen sections of an aldosterone-
producing adenoma incubated
with 125IET-l (100pM). (A)To-
tal binding. A diffuse binding to
APA cells as well as a more in-
tense binding to an arteriolar wall
(asterisks) is evident. (B) BQ-
123 (500 nM) displaces '25I ET-1
binding to the tunica media of an
arteriole (asterisk) without affect-
ing that to the endothelium of the
same vessel and of the capillaries
(arrow). (C) Sarafotoxin 6C
(100 nM) attenuates 125I ET-1
binding to the adenomatous cells
(AC) and even more so to the en-
dothelial lining of capillaries
(arrow). The 125I ET-1 binding to
the tunica media of an arteriole
(asterisk) persist unaffected. AC,
APA cells. *Lumen of an arteri-
ole. Magnification x 145 for all
sections.
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experimental data was provided by a two-site model (Table I).
Thus, our results demonstrate the presence of two endothelin
receptor subtypes. Their respective Kd values appear to be closer
than those found by Molenaar et al. (44) with a quantitative
autoradiography technique in the human myocardium and atrio-
ventricular conducting tissue. However, experiments with mam-
malian cells transfected with cloned cDNAs of the human ETA
and ETB receptors, reported even closer values for the two
receptor subtypes (53-54). The reasons for these discrepancies
are at present unclear, but might relate to the different experi-
mental conditions used in the different studies, which may alter
the accessibility of ET-1 to its receptors.
With the use of specific primers we have been able to am-
plify the cDNA of ET-1, ETA, and ETB genes after reverse-
transcription from total RNA by the random hexamers method.
Indeed, this approach has consistently allowed the amplification
of cDNA fragments of the expected size for each one of the
genes in all specimen tested. In this study the ETA and ETB
mRNA was reverse-transcribed in the same reaction tube,
thereby eliminating the reverse transcription step as a source of
variability in gene dosage. Investigation of the kinetics of PCR
amplification was shown to be valuable for the comparison of
the expression of different genes whenever the efficiency of the
amplification is similar (40). The results of Fig. 5 and the fact
that the N50 of ETB was significantly lower than that of ETA
might suggest a higher initial abundance ofmRNA of the former
receptor. However, several factors, including small differencies
of amplification efficiency, different length and thymidine con-
tent of the amplification products, lack of a deletion/insertion
mutant as an internal standard, and the topographical location
of the specimen used, may affect this conclusion.
To obtain a more precise anatomical location of the receptor
subtypes, we performed autoradiography with "2I ET-l in the
presence and in the absence of BQ-123 and sarafotoxin 6C.
The results of these experiments provide, to the best of our
knowledge, the first evidence of the existence of both receptor
subtypes in the human ZG (Fig. 6). They also confirmed the
expected distribution of the ETA and ETB subtype on the arterio-
lar tunica media and the endothelial lining of the sinusoids,
respectively (Figs. 6 and 7). An intense ET-l binding was
previously detected in the subcapsular lining of the rat adrenal
cortex at autoradiography (22, 25), and also in dispersed ZG
cells in vitro (2). However, the heterogeneity of distribution of
the two receptor subtypes in the different zones and structures
of the adrenal cortex found in our study has some relevant
implications for both the genes expression and the binding ex-
periments studies. They were carried out on tissue homogenates
and therefore are likely to be critically dependent on the topo-
graphical location of the tissue section investigated. Conse-
quently, whilst they clearly show the presence of both ET-1
and its ETA and ETB receptor subtypes, no conclusive informa-
tion on their relative amounts on ZG cells can be gained by
such experiments. Obviously, different methodologies, such as
quantitative autoradiography, in situ PCR, and/or experiments
with cultured ZG cells, are required to address this question.
Nevertheless, taken altogether our results demonstrate that
both the ET-l and its ETA and ETB receptor subtypes genes are
transcribed and translated into protein in the adrenal cortex, as
well as in a tumor that is histogenetically derived from the ZG
cells. It is additionally shown that the level of transcripts of
both receptors was higher in the adrenal than in the renal cortex
of the same patient with APA (Fig. 3 B), a finding that support
the concept of a major role of ET-1 in the paracrine regulation
of aldosterone secretion. This role is further underlined by at
least two sets of evidence: first, ZG cells appear to be able
to distinguish between the stimulation of phosphatidylinositol
turnover induced by ET-1 and those triggered by angiotensin
II and vasopressin (47); second, ET-1 is capable of downregu-
lating its receptors by enhancing internalisation of the hormone-
receptor complex (55).
A final comment deserves our finding that both the ETA and
ETB receptor subtypes were detected in an APA, as well as in
the surrounding histologically normal cortex, at the level of
gene expression and also with 1251 ET-1 displacement binding
and autoradiography experiments (Fig. 7). Of interest, in five
patients with primary aldosteronism Zeng et al. (56) reported
that endothelin stimulated the secretion of aldosterone in vitro
from the cortex surrounding aldosterone-producing adenomas
in a dose-dependent fashion, but not from the tumors. Although
further studies are needed before drawing more definitive con-
clusions, our experiments provide evidence that the mRNAs for
both the ETA and ETB receptor subtypes are detectable and that
these receptors can be functionally measured in the APA tissue.
In addition, lower B., values of both receptor subtypes and a
less intense '25I ET-1 binding at autoradiography (Fig. 7) were
observed in the APA tissue. Accordingly, these findings- may
suggest that the absence of aldosterone response in vitro to ET-
1 is not due to lack of expression of the genes encoding for the
two ET-1 receptor subtypes, but may rather be ascribed to a
decreased rate of transcription resulting in a lower density of
the density of both receptors in the tumor tissue as compared
to the normal adrenal cortex.
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